What Is Retatrutide?

Retatrutide is a peptide-based investigational compound developed to activate three metabolic hormone receptors within a single molecule. It is being evaluated for its potential effects on appetite regulation, glucose metabolism, lipid metabolism and energy expenditure.

Retatrutide differs from single-receptor compounds such as semaglutide and dual-receptor compounds such as tirzepatide. Its scientific significance comes from the interaction among all three receptor pathways rather than from a simple or direct “fat-burning” effect.

How Does Retatrutide Work?

GLP-1 receptor activation

GLP-1 is an incretin hormone involved in post-meal glucose regulation and appetite signalling. GLP-1 receptor activity is associated with:

• Glucose-dependent insulin secretion
• Reduced glucagon secretion under certain conditions
• Delayed gastric emptying
• Central signalling associated with appetite and satiety

GIP receptor activation

GIP is another incretin hormone involved in nutrient handling and insulin signalling. Researchers are investigating whether combined GLP-1 and GIP activity can produce broader metabolic effects than GLP-1 activity alone.

• Supports glucose-dependent insulin responses
• Influences nutrient and lipid metabolism
• May complement GLP-1 receptor signalling
• May affect adipose-tissue biology

Glucagon receptor activation

Glucagon receptor activity is the feature that most clearly distinguishes retatrutide from established single- and dual-agonist compounds. This pathway may affect hepatic metabolism and energy expenditure.

Glucagon activity can also increase hepatic glucose production. Consequently, researchers must evaluate the balance between potential effects on energy expenditure and possible glucose-related risks. The interaction of all three pathways is more complex than a standalone fat-oxidation mechanism.

What Did the Phase 2 Obesity Trial Find?

A randomised Phase 2 trial published in the New England Journal of Medicine assessed retatrutide in 338 adults with obesity or overweight and at least one weight-related condition. Participants in this trial did not have diabetes.

These results are group averages from a controlled clinical trial. They do not guarantee an individual outcome and must not be used to create personal treatment expectations or dosing plans.

It is also important not to confuse the reported 24.2% mean weight reduction with a 24 mg dose. The highest maintenance dose evaluated in the published Phase 2 obesity trial was 12 mg once weekly.

Findings Beyond Body Weight

Clinical research has also examined measurements beyond total body weight. Reported findings have included changes in:

• Waist circumference
• Blood pressure
• Fasting glucose and insulin-related measurements
• Triglycerides and other lipid measurements
• Liver fat in selected research populations

These findings are scientifically important, but they do not by themselves prove that retatrutide prevents or treats cardiovascular disease, diabetes, fatty liver disease or another medical condition. Disease-specific benefits must be established through appropriately designed trials.

Safety Findings and Research Limitations

The most frequently reported adverse events in the Phase 2 obesity trial were gastrointestinal. They were generally mild to moderate and occurred more often during dose escalation.

• Nausea
• Diarrhoea
• Vomiting
• Constipation
• Reduced appetite

Dose-dependent increases in heart rate were also observed. Larger and longer studies are needed to assess uncommon adverse events, discontinuation rates, long-term cardiovascular outcomes and what happens after treatment is stopped.

Is Retatrutide Available as an Approved Medicine?

Retatrutide has been studied as an investigational compound. Regulatory status can change, so readers in the United Kingdom should consult the official Medicines and Healthcare products Regulatory Agency for current authorisation information.

Terms such as “research-grade,” “compounded” and “independently tested” do not mean that a product has been authorised as a medicine or shown to be safe for personal administration.

Frequently Asked Questions

Scientific Sources and Further Reading

1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial . New England Journal of Medicine, 2023.
2. PubMed: Retatrutide Phase 2 obesity trial record .
3. NIHR Be Part of Research: Retatrutide clinical research information .